Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Apellis Pharmaceuticals, Inc. (APLS) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer listed on the Nasdaq Global Select Market, Apellis uses filings such as Forms 10-K, 10-Q, 8-K, and others to report on its business, financial condition, risk factors, and material events related to its complement-based therapies SYFOVRE and EMPAVELI/Aspaveli.
In these filings, investors can review detailed information on revenue from SYFOVRE and EMPAVELI, research and development spending for ophthalmology and rare disease programs, and the status of key clinical trials such as GALE and VALIANT. Risk factor and management discussion sections typically describe the scientific and regulatory considerations associated with targeting C3 in geographic atrophy, C3 glomerulopathy, primary IC-MPGN, and paroxysmal nocturnal hemoglobinuria.
Current reports on Form 8-K, such as the Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi), document material definitive agreements that affect Apellis’ economics, including ex-U.S. royalty structures for Aspaveli and related financing consents. These filings help clarify how collaborations and capital arrangements support the company’s commercialization and pipeline strategy.
On Stock Titan, Apellis filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly understand topics like royalty arrangements, cash runway, product revenue trends, and major clinical or regulatory milestones. Users can also review Forms 4 and other insider transaction reports to monitor trading activity by Apellis directors and executives, alongside proxy and governance disclosures that describe compensation and board oversight. This page is a central resource for analyzing the regulatory record behind APLS stock.
Apellis Pharmaceuticals Chief Financial Officer Timothy Eugene Sullivan reported two bona fide gift transfers of common stock. On April 17, 2026, he gifted a total of 22,192 shares, including 11,096 shares transferred to The Timothy E Sullivan Irrevocable Trust of 2023.
After these gifts, the filing shows 71,492 shares held indirectly through the irrevocable trust and 140,945 shares held directly. The footnote states he disclaims beneficial ownership of shares held by the trust except to the extent of his pecuniary interest.
Apellis Pharmaceuticals, Inc. recommends that its stockholders accept the tender offer from Biogen to acquire all outstanding common shares for $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share that can pay up to $4.00 upon achievement of specified sales milestones. Apellis reports 128,007,815 Shares issued and outstanding as of April 9, 2026. The Apellis Board unanimously determined the offer is fair, approved the merger agreement and related CVR agreement, and recommends tendering; certain directors, executives and Morningside (support stockholders) agreed to tender and together hold approximately 14% of outstanding Shares. The offer initially expires one minute after 11:59 p.m. Eastern Time on May 13, 2026, and the merger will be effected by a tender offer followed by a Section 251(h) merger if conditions are met.
Biogen Inc. launches a tender offer to acquire Apellis Pharmaceuticals for $41.00 per share plus a contingent value right. Purchaser Aspen Purchaser Sub, a Biogen subsidiary, offers $41.00 in cash per Apellis share and one non-transferable contingent value right per share for up to an aggregate $4.00 upon specified milestones under a Contingent Value Rights Agreement, each subject to the terms of the Offer to Purchase. Apellis had 128,007,815 shares outstanding as of April 9, 2026, with additional potential dilution from convertible notes of $93,897,000 (convertible at 25.3405 shares per $1,000) and awarded equity awards described in the filing. The offer and the Merger Agreement govern the transaction; the Offer to Purchase, Letter of Transmittal, and merger documents are incorporated by reference.
Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported an internal share restructuring involving her spouse's holdings. A total of 5,750 shares of Common Stock were distributed from a trust to an account held directly by her spouse, and her beneficial ownership is unchanged. Following this, she reports 25,666 shares held directly and 5,750 shares held indirectly through her spouse.
Biogen Inc., through its wholly owned subsidiary Aspen Purchaser Sub, Inc., provided pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals, Inc. pursuant to the Agreement and Plan of Merger dated March 31, 2026.
The communication states the tender offer has not commenced and that formal offer materials will be filed on Schedule TO at commencement; it urges Apellis securityholders to review the eventual offer documents and the solicitation/recommendation statement on Schedule 14D-9.
Apellis Pharmaceuticals ownership filing: Wellington Management Group LLP and related Wellington entities report beneficial ownership of 249,635 shares of Apellis common stock, representing 0.20% of the class as of 03/31/2026. The filing states shared voting power of 239,469 and shared dispositive power of 249,635.
BIOGEN INC. filed an initial ownership report for its relationship with Apellis Pharmaceuticals, Inc. under a Tender and Support Agreement dated March 31, 2026. The agreement covers common stock held by several existing Apellis holders and may form a “group” that beneficially owns in aggregate more than 10% of the outstanding common stock for Section 13(d) purposes.
However, the agreement does not give Biogen any pecuniary interest in the Apellis common stock, related RSUs, or options, so Biogen is not considered a beneficial owner for Section 16 reporting. The Form 3 shows zero indirect holdings of common stock and stock options following the reporting date.
Biogen Inc. has filed a Schedule 13D reporting beneficial ownership of 18,469,475 shares of Apellis Pharmaceuticals common stock, representing 14.2% of the class as of March 31, 2026, due to a tender and support agreement with key Apellis stockholders.
Biogen, through wholly owned subsidiary Aspen Purchaser Sub, Inc., agreed to launch a tender offer to acquire all outstanding Apellis shares for $41.00 in cash per share plus one non-transferable contingent value right (CVR) per share. Each CVR may pay up to an additional $4.00 in cash if specified net sales milestones for SYFOVRE and related products of at least $1.5 billion or $2.0 billion in certain years from 2027 to 2031 are achieved.
The offer will be open for 20 business days, followed by a merger under Section 251(h) of Delaware law that will make Apellis a wholly owned Biogen subsidiary and lead to delisting of Apellis common stock. Biogen plans to finance the merger with cash on hand and term loan proceeds.
Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.
Apellis Pharmaceuticals agreed to be acquired by Biogen through a cash tender offer and follow‑on merger. Biogen will offer Apellis stockholders $41.00 in cash per share plus a non‑transferable contingent value right (CVR) that can pay up to an additional $4.00 per share in cash if specified SYFOVRE® annual global net sales milestones are met. The implied upfront transaction value is approximately $5.6 billion. A tender offer will run for 20 business days, subject to customary conditions including a majority tender, antitrust clearance under the HSR Act and other standard closing conditions. Apellis’ board unanimously approved the deal and recommends stockholders tender their shares. Certain directors, executives and a major stockholder holding about 14% of Apellis shares signed a tender and support agreement to back the transaction.